Evidence map›Paper›PMID 41279806›Full record

ArticlebioRxiv : the preprint server for biology2025

Epigenetic control of microglial developmental milestones from proliferative progenitors to efficient phagocytes.

Marta Pereira-Iglesias, Duncan Martinson, Carles Falco, Joel Maldonado-Teixido, Marco González-Domínguez, Rodrigo Senovilla-Ganzo, Sol Beccari, Jorge Valero, Bella Mora-Romero, Ivan Ballasch and 20 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Marta Pereira-IglesiasAchucarro Basque Center for Neuroscience, Science Park University of the Basque Country EHU/UPV, Leioa, Spain.
Duncan MartinsonThe Francis Crick Institute, London, UK.
Carles FalcoMathematical Institute, Oxford University, Oxford, UK.
Joel Maldonado-TeixidoAchucarro Basque Center for Neuroscience, Science Park University of the Basque Country EHU/UPV, Leioa, Spain.
Marco González-DomínguezAchucarro Basque Center for Neuroscience, Science Park University of the Basque Country EHU/UPV, Leioa, Spain.
Rodrigo Senovilla-GanzoAchucarro Basque Center for Neuroscience, Science Park University of the Basque Country EHU/UPV, Leioa, Spain.
Sol BeccariAchucarro Basque Center for Neuroscience, Science Park University of the Basque Country EHU/UPV, Leioa, Spain.
Jorge ValeroInstitute of Neuroscience of Castilla y León - INCyL, Universidad de Salamanca, Salamanca, Spain.
Bella Mora-RomeroInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Seville, Spain.
Ivan BallaschDepartament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Sarah ViguierCentre interdisciplinaire de recherche en biologie (CIRB), Collège de France, CNRS, Inserm, Université PSL Paris France.
Philipp HaneInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Molly BoettigerDepartment of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Julie A ReiszDepartment of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, USA.ORCID 0000-0002-7296-4963
Alba Elías-TersaCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
Yasmina MansoCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
Laura ParkkinenNuffield Department of Clinical Neurosciences, University of Oxford, Level 6 West Wing, John Radcliffe Hospital, Oxford OX3 9DU, UK.0.
Ana María AransayCICbioGUNE, Genome analysis platform, Derio, Spain.
Federico N SoriaAchucarro Basque Center for Neuroscience, Science Park University of the Basque Country EHU/UPV, Leioa, Spain.ORCID 0000-0003-1229-9663
Angelo D AlessandroDepartment of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, USA.ORCID 0000-0002-2258-6490
Eduardo SorianoCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.ORCID 0000-0001-9260-9291
Morgane S ThionCentre interdisciplinaire de recherche en biologie (CIRB), Collège de France, CNRS, Inserm, Université PSL Paris France.ORCID 0000-0003-2364-8451
Sonia GarelCentre interdisciplinaire de recherche en biologie (CIRB), Collège de France, CNRS, Inserm, Université PSL Paris France.ORCID 0000-0003-2984-3645
Melanie GreterInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-7220-5369
Albert GiraltDepartament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0001-5334-0963
Alberto PascualInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Seville, Spain.ORCID 0000-0001-5459-6207
Fernando García-MorenoAchucarro Basque Center for Neuroscience, Science Park University of the Basque Country EHU/UPV, Leioa, Spain.ORCID 0000-0001-9048-4237
David A MenassaNuffield Department of Clinical Neurosciences, University of Oxford, Level 6 West Wing, John Radcliffe Hospital, Oxford OX3 9DU, UK.0.ORCID 0000-0002-5984-8407
Jose A CarrilloMathematical Institute, Oxford University, Oxford, UK.ORCID 0000-0001-8819-4660
Amanda SierraAchucarro Basque Center for Neuroscience, Science Park University of the Basque Country EHU/UPV, Leioa, Spain.ORCID 0000-0001-8415-096X

Funding

Dissecting the Etiology of The Lewy Body DementiasR01NS124848 · NINDS · J. DAVID GLADSTONE INSTITUTES · PI STEVEN M FINKBEINER · 2025 to 2026
$1.6M
NINDS NIH HHS R01 NS124848
6 · The paper itself

Abstract

Early immune perturbations increase the risk of neurodegenerative and neurodevelopmental disorders, yet the mechanisms underlying the maturation of microglia, the resident immune cells of the brain parenchyma, remain poorly defined. Specifically, how proliferation, morphological differentiation, and phagocytosis are coordinated among microglia progenitors as they colonize the embryonic brain remains unclear. Here, we combined mathematical modeling with spatiotemporal analyses of the murine hippocampus and cerebellum from postnatal day 2 (P2) to P60 to reconstruct the trajectory of microglial development. We identified a proliferative-to-quiescent (P/Q) switch around P3/P4 that preceded the acquisition of morphological complexity and efficient phagocytosis and was accompanied by coordinated shifts in cell-cycle dynamics and metabolic state. Strikingly, this P/Q switch was recapitulated in repopulation contexts in mice and in the human fetal brain, where later stages displayed enhanced phagocytic function coupled to reduced proliferation. Perturbing the proliferative phase through pharmacological or genetic disruption of CSF1R signaling impaired subsequent microglial complexity and phagocytosis efficiency, revealing an unexpected reliance of phagocytosis on proliferation-driven colonization. Finally, we show that microglia stepwise maturation during development is associated with chromatin remodeling and driven by the epigenetic regulator Ikaros. Together, these findings uncover the sequential milestones of microglial development, revealing a potential period of early vulnerability and establishing an unexpected linkage between proliferation and phagocytosis essential to understanding how these processes are coordinated in neurodegenerative disorders.

Indexed as

Bayesian parameter inferencedevelopmentepigenetic modulatorsIkarosmicrogliaphagocytosispopulation modelingproliferation

Identifiers

PMID41279806
PMCPMC12637658

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.